Cambridge Healthtech Institute Announces World Preclinical Congress

NEEDHAM, Mass. - July 31, 2015 - PRLog -- Cambridge Healthtech Institute’s Fifteenth Annual World Preclinical Congress: Making a commitment to focus predominantly on preclinical research and highlight the challenges and opportunities in early drug discovery and development. Bringingtogether some of the hottest topics being discussed in the pharma/biotech world and providing a unique forum for scientists and clinicians to exchange ideas and collaborate to overcome some of the translational challenges. This coincides with the event moving to Boston, now a premier hub for preclinical activity and alliances.

Highlights of WPC:

·         13 conferences on some of the hottest topics in preclinical research

·         11 short courses offering interactive discussions with experts in the field

·         Breakout discussions on key topics organized in an informal setting

·         Training seminar: Applying Pharmacology to New Drug Discovery

·         Plenary Keynote presentation by a key opinion leader

·         Large exhibit hall offering a glimpse at the latest tools and reagents

·         Poster sessions featuring cutting-edge, ongoing research

·         Networking opportunities to meet with a global gathering of scientists from academia and industry

·         Inter-disciplinary forum to meet chemists, biologists, toxicologists and people from various backgrounds

·         Student Fellowships to bring together young researchers looking to make a difference

·         Exclusive focus on ideas, technologies and interests driving preclinical decision-making

·         Sponsored talks by leading technology and service providers showcasing new offerings


Conferences included in WPC:

·         Mastering Medicinal Chemistry

·         Property Based Drug Design

·         Tumor Models for Targeted Therapy

·         Tumor Models for Immunotherapy

·         Imaging for Oncology

·         3D Cell Models

·         Blood Brain Barrier

·         Chemical Biology

·         Chemical Proteomics

·         Functional Genomics Technologies

·         Targeting GPCRs

·         Targeting Histone Acetylation

·         Predicting Drug Toxicity

Confirmed Speakers Include:

David Kaufman, M.D., Ph.D., Director/Senior Principal Scientist, Oncology/Immunotherapy Clinical Research, Merck

Peter Grootenhuis, Ph.D., Senior Director, Chemistry, Vertex Pharmaceuticals

Phillip Pang, M.D., Ph.D., Director, Clinical Research, Gilead Sciences

David Stresser, Ph.D., Program Manager, Corning Gentest Contract Research Services

Mingxiang Liao, Ph.D., Senior Scientist I, Department of Drug Metabolism and Pharmacokinetics, Takeda Pharmaceutical Intl. Company

King C. Li, M.D., FRCP(C), MBA, Senior Associate Dean for Clinical and Translational Research; Professor and Chair, Department of Radiology, Wake Forest School of Medicine

John Erve, Ph.D., DABT, Jerve Scientific Consulting, Inc.

Lawrence Berliner, Ph.D., Professor of Chemistry and Biochemistry, University of Denver; Emeritus, Ohio State University

Qin Wang, Ph.D., Principal Scientist, Translational Sciences, Biogen Idec

Margareta Hammarlund-Udenaes, Ph.D., Professor, Translational PK/PD, Department of Pharmaceutical Biosciences, Uppsala University

Arthur M. "Buzz" Brown, M.D., Ph.D., Managing Director, ChanTest, a Charles River Company

Bernard Fermini, Ph.D., Associate Research Fellow, Global Safety Pharmacology, Pfizer Global Research & Development

Gary Gintant, Ph.D., Research Fellow, Integrative Pharmacology, Abbvie

Richard B. Bankert, V.M.D., Ph.D., Professor, Department of Microbiology and Immunology, State University of New York at Buffalo

Neal Goodwin, Ph.D., Vice President Corporate Research Development Champions Oncology, Inc

Jeremy N. Ruskin, M.D., Professor of Medicine, Harvard Medical School; Director, Cardiac Arrhythmia Service, Massachusetts General Hospital

To view the entire conference agenda and to register, please visit: http://www.worldpharmacongress.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.